

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

| | | |
|--------------------------------|---|-------------------------------|
| ATTY. DOCKET NO. 05213-0229 | SERIAL NO. NOT YET AVAILABLE 10/042347 | FILING DATE Filed Herewith |
| APPLICANT O'REILLY, ET AL | | GROUP |

JP997 U.S. PTO
10/042347
01/11/98

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|-----------------|------|------|-------|----------|-------------------------------|
| AA | | | | | | |
| AB | | | | | | |
| AC | | | | | | |
| AD | | | | | | |
| AE | | | | | | |
| AF | | | | | | |
| AG | | | | | | |
| AH | | | | | | |
| AI | | | | | | |
| AJ | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | NAME | TRANSLATION YES NO. |
|-----|-----------------|----------|------------------|------|------------------------|
| STN | AK WO 95/29242 | 11/02/95 | PCT | | |
| | AL WO 95/25543 | 09/28/95 | PCT | | |
| | AM WO 93/16716 | 09/02/93 | PCT | | |
| | AN WO 91/10424 | 07/25/91 | PCT | | |
| | AO J58036391 | 03/03/83 | Japan (Abstract) | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----|--|
| AP | |
| AR | |
| AS | |
| AT | |

| | |
|-------------------------|----------------------------|
| EXAMINER <i>Ally</i> | DATE CONSIDERED 9/20/04 |
|-------------------------|----------------------------|

EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

| | | | |
|---|----|--|----------------|
| ATTY. DOCKET NO. | | SERIAL NO. | FILING DATE |
| 05213-0229 | | NOT YET AVAILABLE | Filed Herewith |
| APPLICANT | | GROUP | |
| O'REILLY, ET AL | | 10/04/2347 | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| 54 | BA | Abe, N. et al., "Identification of a Novel Collagen Chain Represented by Extensive Interruptions in the Triple-Helical Region", <i>Biochem. and Biophys. Resch. Comm.</i> , Vol. 196, No. 2, pp. 576-582 (1993) | |
| | BB | Algire, G.H. et al., "Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants", <i>J. Natl. Canc. Inst.</i> , Vol. 6, pp. 73-85 (1945) | |
| | BC | Angiolillo, A.I. et al., "Human interferon-inducible Protein 10 is a potent inhibitor of angiogenesis in vivo", <i>J. Exp. Med.</i> , Vol. 182, pp. 155-162 (1995) | |
| | BD | Brcm, H. et al., "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas", <i>J. Neurosurg.</i> , Vol. 74, pp. 441-446 (1991) | |
| | BE | Brockway, W. J. et al., "Measurement of the Binding of Antifibrinolytic Amino Acids to Various Plasminogens", <i>Arch. Biochem. Biophys.</i> , Vol. 151, pp. 194-199 (1972) | |
| | BF | Browne, M.J. et al., "Expression of Recombinant Human Plasminogen and Aglycoplasminogen in HeLa Cells", <i>Fibrinolysis</i> , Vol. 5, pp. 257-260 (1991) | |
| | BG | Cao, Y. et al., "gro-β, α-C-X-C- Chemokine, Is an Angiogenesis Inhibitor That Suppresses the Growth of Lewis Lung Carcinoma in Mice", <i>J. Exp. Med.</i> , Vol. 182, pp. 2069-2077 (1995) | |
| | BH | Chen, C. et al., "A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors", <i>Canc Resch.</i> , Vol. 55, pp. 4230-4233 (1995) | |
| | BI | Clapp, C. et al., "The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis", <i>Endocrinology</i> , Vol. 133, pp. 1292-1299 (1993) | |
| | BJ | Cleary, S. Mulkerrin et al., "Purification and Characterization of Tissue Plasminogen Activator Kringle-2 Domain Expressed in <i>Escherichia coli</i> ", <i>Biochem.</i> , Vol. 28, pp. 1884-1891 (1989) | |
| | BK | Dameron, K.M. et al., "Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1", <i>Science</i> , Vol. 265, pp. 1582-1584 (1994) | |
| | BL | Folkman, J., "Tumor angiogenesis and tissue factor", <i>Nature Med.</i> Vol. 2, pp. 167-168 (1996) | |
| | BM | Folkman, J., "What is the Evidence that Tumors are Angiogenesis Dependent?", <i>J. Natl Canc Inst.</i> , Vol. 82, pp. 4-6 (1990) | |
| | BN | Folkman, J., "Angiogenesis in cancer, vascular, rheumatoid and other disease", <i>Nature Medicine</i> , Vol. 1, No. 1, pp. 27-31 (1995) | |
| | BO | Folkman, J., "Long-term culture of capillary endothelial cells", <i>Proc. Natl. Acad. Sci. USA</i> 76, pp. 5217-5221 (1979) | |
| | BP | Folkman, J. et al., "Induction of angiogenesis during the transition from hyperplasia to neoplasia", <i>Nature</i> , Vol. 339, pp. 58-61 (1989) | |
| | BQ | Folkman, J. et al., "Tumor Behavior in Isolated Perfused Organs In Vitro Growth and Metastases of Biopsy Material in Rabbit Thyroid and Canine Intestinal Segment", <i>Annals of Surgery</i> , Vol. 164, No. 3, pp. 491-501 (1996) | |
| | BR | Folkman, J., "Angiogenesis and Its Inhibitors", <i>Important Advances in Oncology</i> , J.B. Lippincott Company, pp. 42-62 (1985) | |
| | BS | Folkman, J., "Tumor Angiogenesis Therapeutic Implications", <i>NE J. of Med.</i> , No. 18, pp. 1182-1186 (1971) | |
| EXAMINER | | DATE CONSIDERED | |
| EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | 7/20/04 | |

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

| | | | |
|---|----|---|----------------|
| ATTY. DOCKET NO. | | SERIAL NO. NOT YET AVAILABLE | FILING DATE |
| 05213-0229 | | 10/042347 | Filed Herewith |
| APPLICANT | | GROUP | |
| O'REILLY, ET AL | | | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| 554 | CA | Gavrieli, Y. et al., "Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation", <i>J. Cell Biol.</i> , Vol. 119, pp. 493-501 (1992) | |
| | CB | Gimbrone, M.A. et al., "Tumor Growth and Neovascularization An Experimental Model using the Rabbit Cornea", <i>J. Natl. Canc. Inst.</i> , Vol. 52, No. 2 pp. 413-427 (1974) | |
| | CC | Gimbrone, M.A. et al., "Tumor Dormancy in Vivo by Prevention of Neovascularization", <i>J. of Experi. Med.</i> , Vol. 136, pp. 261-276 (1972) | |
| | CD | Good, D.J. et al., "A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin", <i>Proc. Nat. Acad. Sci. USA</i> , Vol. 87, pp. 6624-6628 (1990) | |
| | CE | Grant, D.S. et al., "Scatter factor induces blood vessel formation in vivo", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 99, pp. 1937-1941 (1993) | |
| | CF | Grant, D.S. et al., "Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro", <i>Cell</i> , Vol. 58, pp. 933-943 (1989) | |
| | CG | Gross, J.L. et al., "Modulation of Solid Tumor Growth in vivo by bFGF", <i>Proc. Amer. Assoc. Canc. Resh.</i> , Vol. 31, p. 79 (1990) | |
| | CH | Gross, J.L. et al., "Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro.", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 80, pp. 2623-2627 (1983) | |
| | CI | Gunzler, W.A. et al., "The Primary Structure of High Molecular Mass Urokinase from Human Urine", <i>Hoppe-Seyler's Z. Physiol. Chem.</i> , Vol. 363, pp. 1155-1165 (1982) | |
| | CJ | Gupta, S.K. et al., "A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 7779-7803 (1995) | |
| | CK | Holmgren, L. et al., "Dormancy of micrometastases Balanced proliferation and apoptosis in the presence of angiogenesis suppression", <i>Nature Medicine</i> , Vol. 1, No. 2, pp. 149-153 (1995) | |
| | CL | Homandberg, G.A. et al., "Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth", <i>Am. J. Path.</i> , Vol. 120, pp. 327-332 (1985) | |
| | CM | Hori, A. et al., "Suppression of Solid tumor Growth by Immunoneutralizing Monoclonal Antibody against Human Basic Fibroblast Growth Factor", <i>Canc. Resch.</i> , Vol. 51, pp. 6180-6184 (1991) | |
| | CN | Ingber, D. et al., "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth", <i>Nature</i> , Vol. 348, pp. 555-557 (1990) | |
| | CO | Johansson, J. et al., "Surfactant Protein B: Disulfide Bridges, Structural Properties, and Kringle Similarities", <i>Biochem.</i> , Vol. 30, pp. 6917-6921 (1991) | |
| | CP | Kandel, J. et al., "Neovascularization is Associated with a Switch to the Export of bFGF in the Multistep Development of Fibrosarcoma", <i>Cell</i> , Vol. 66, pp. 1095-1104 (1991) | |
| | CQ | Kim, K. J. et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo", <i>Nature</i> , Vol. 362, pp. 841-844 (1993) | |
| | CR | Kivirikko, S. et al., "Primary Structure of the $\alpha 1$ Chain of Human Type XV Collagen and Exon-Intron Organization in the 3' Region of the Corresponding Gene", <i>J. Bio. Chem.</i> , Vol. 269, No. 7, pp. 4773-4779 (1994) | |
| EXAMINER | | DATE CONSIDERED | |
| EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | 9/20/04 | |

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

| | | | |
|---|----|---|----------------|
| ATTY. DOCKET NO. | | SERIAL NO. NOT YET AVAILABLE | FILING DATE |
| 05213-0229 | | | Filed Herewith |
| APPLICANT | | GROUP | |
| O'REILLY, ET AL | | 10/04/2347 | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| SM | DA | Knighton, D. et al., "Avascular and Vascular Phases of Tumor Growth in the Chick Embryo", <i>Br. J. Cancer</i> , Vol. 35, pp. 347-356 (1977) | |
| | DB | Lein, W. M. et al., "The blood supply of experimental liver metastases. II. A Microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber", <i>Surgery</i> , Vol. 68, No. 2, pp. 334-340 (1970) | |
| | DC | Lerch et al., "Localization of Individual Lysine-Binding Regions in Human Plasminogen and Investigations on Their Complex-Forming Properties", <i>European Journal of Biochemistry</i> , Vol. 107, No. 1, pp. 7-13 (1980) | |
| | DD | Lokker, N.A. et al., "Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-met receptor", <i>Prot. Engin.</i> , Vol. 7, pp. 895-903 (1994) | |
| | DE | Maione, T.E. et al., "Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides", <i>Science</i> , Vol. 247, pp. 77-79 (1990) | |
| | DF | Marti, D. et al., "Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for ω -aminocarboxylic acids", <i>Eur. J. Biochem.</i> , Vol. 219, pp. 455-462 (1994) | |
| | DG | McLean, J.W. et al., "cDNA sequence of human apolipoprotein(a) is homologous to plasminogen", <i>Nature</i> , Vol. 330, pp. 132-137 (1987) | |
| | DH | Menhart, N. et al., "Construction, Expression, and Purification of Recombinant Kringle 1 of Human Plasminogen and Analysis of Its Interaction with ω -Amino Acids", <i>Biochem.</i> , Vol. 30, pp. 1948-1957 (1991) | |
| | DI | Millauc, B. et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant", <i>Nature</i> , Vol. 367, pp. 576-579 (1994) | |
| | DJ | Moses, M.A. et al., "Identification of an Inhibitor of Neovascularization from Cartilage", <i>Science</i> , Vol. 248 (1990) | |
| | DK | Muragaki, Y. et al., "Mouse col 18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 8763-8767 (1995) | |
| | DL | Muthukkaruppan, V.R., "Angiogenesis in the Mouse Cornea", <i>Science</i> , Vol. 205, pp. 1416-1418 (1979) | |
| | DM | Nelson, J. A. et al., "Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF- and laminin-dependent endothelial cell motility and angiogenesis", <i>Canc. Resch.</i> , Vol. 55, pp. 3772-3776 (1995) | |
| | DN | Nguyen, M. et al., "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane", <i>Microvascular Research</i> , Vol. 47, pp. 31-49 (1994) | |
| | DO | Nguyen, M. et al., "Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients", <i>J. of Nat. Canc. Inst.</i> , Vol. 85, No. 3, pp. 241-242 (1993) | |
| | DP | O'Reilly et al., "Endogenous Inhibitors of Angiogenesis", <i>Proc. Am. Assoc. Canc. Resch.</i> , Vol. 37, p. 669 (1996) | |
| | DQ | O'Reilly et al., "Angiostatin induces and sustains dormancy of human primary tumors in mice", <i>Nature Medicine</i> , Vol. 2, No. 6, pp. 689-692 (1996) | |
| | DR | O'Reilly et al., "The suppression of Tumor Metastases by a Primary Tumor", <i>Surgical Forum</i> , Vol. XLIV, pp. 474-476 (1993) | |
| | DS | O'Reilly et al., "Angiostatin A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", <i>Cell</i> , Vol. 79, pp. 315-328 (1994) | |
| | DT | O'Reilly et al., "Angiostatin: A Circulating Endothelial Cell Inhibitor That Suppresses Angiogenesis and Tumor Growth", <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , Vol. LIX, pp. 471-482 (1994) | |
| | DU | Obeso, J. et al., "Methods in Laboratory Investigation/A Hemangioendothelioma-Derived Cell Line Its Use as a Model for the Study of Endothelial Cell Biology", <i>Laboratory Investigation</i> , Vol. 63, No. 2, p. 159 (1990) | |
| | DV | Oh, S.K. et al., "Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 4229-4233 (1994) | |
| EXAMINER | | DATE CONSIDERED | |
| EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | 9/20/04 | |

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

| | | | |
|---|----|---|----------------|
| ATTY. DOCKET NO. | | SERIAL NO. NOT YET AVAILABLE | FILING DATE |
| 05213-0229 | | | Filed Herewith |
| APPLICANT | | GROUP | |
| O'REILLY, ET AL | | 10/042347 | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| 5571 | EA | Oh, S.P., "Cloning of cDNA and Genomic DNA Encoding Human Type VIII Collagen and Localization of the $\alpha 1$ (XVIII) Collagen Gene to Mouse Chromosome 10 and Human Chromosome 21", <i>Genomics</i> , Vol. 19, pp. 494-499 (1994) | |
| | EB | Parangi, S. et al., "Antiangiogenic therapy of transgenic mice impairs de novo tumor growth", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 2002-2007 (1996) | |
| | EC | Passaniti, A. et al., "Methods in Laboratory Investigation/A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor", <i>Lab. Invest.</i> , Vol. 67, No. 4, pp. 519-528 (1992) | |
| | ED | Ponting et al., "Plasminogen: a structural review", <i>Blood Coagulation and Fibrinolysis</i> , Vol. 3, pp. 605-614 (1992) | |
| | EE | Powell, J. R. et al., "Amino Acid Sequence Analysis of the Asparagine-288 Region of the Carbohydrate Variants of Human Plasminogen", <i>Biochem.</i> , Vol. 22, pp. 923-927 (1983) | |
| | EF | Rastinejad, F. et al., "Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene", <i>Cell</i> , Vol. 56, pp. 345-355 (1989) | |
| | EG | Rehn, M. et al., " $\alpha 1$ (XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 4234-4238 (1994) | |
| | EH | Rehn, M. et al., "Identification of three N-terminal ends of type XVIII collagen chains and tissue-specific differences in the expression of the corresponding transcripts", <i>J. Biol. Chem.</i> , Vol. 270, pp. 5705-4711 (1995) | |
| | EI | Robbins, K.C., "The Plasminogen-Plasmin Enzyme System", <i>Fibrinolysis</i> , pp. 340-357 (1987) | |
| | EJ | Sage, E.H. et al., "Inhibition of Endothelial Cell Proliferation by SPARC is Mediated through a Ca^{2+} -Binding EF-Hand Sequence", <i>J. Cell. Biochem.</i> , Vol. 57, pp. 127-140 (1995) | |
| | EK | Sakamoto, N. et al., "Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH ₂ ", <i>Canc. Resch.</i> , Vol. 51, pp. 903-906 (1991) | |
| | EL | Sambrook, J. et al., "Expression of Cloned Genes in Escherichia coli", <i>Molecular Cloning Second Edition</i> , Cold Spring Harbor Laboratories Press, pp. 17.37-17.41 | |
| | EM | Schaller, J. et al., "Structural Aspects of the Plasminogen of Various Species", <i>Enzyme</i> , 40 pp. 63-69 (1988) | |
| | EN | Shi, G. et al., "Kringle Domains and Plasmin Denaturation", <i>Biochem. Biophys. Resch. Comm.</i> , Vol. 178, No. 1, pp. 360-368 (1991) | |
| | EO | Sottrup-Jensen, L. et al., "The Primary Structure of Human Plasminogen Isolation of Two Lysine-Binding Fragments and One "Mini-" Plasminogen (MW, 38,000) by Elastase-Catalyzed-Specific Limited Proteolysis", <i>Prog. in Chem. Fibrinolysis and Thrombolysis</i> , Vol. 3, pp. 191-209 (1978) | |
| | EP | Srivastava, A. et al., "The Prognostic Significance of Tumorascularity in Intermediate-Thickness (0.76-4.0mm Thick) Skin Melanoma", <i>Am. J. of Path.</i> , Vol. 133, No. 2, pp. 419-424 (1988) | |
| | EQ | Strieter, R.M. et al., "Interferon-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis", <i>Biochem. Biophys. Resch. Comm.</i> , Vol. 210, pp. 51-57 (1995) | |
| | ER | Studier, W.F. et al., "Use of T7 RNA polymerase to direct expression of cloned genes", <i>Methods Enzymol.</i> , Vol. 85, pp. 60-89 (1990) | |
| | ES | Teicher, B.A. et al., "Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents", <i>Int. J. Canc.</i> , Vol. 57, pp. 1-6 (1994) | |
| | ET | Tolsma, S.S. et al., "Peptides derived from two separate domains of the matrix protein thrombospondin-1 have antiangiogenic activity", <i>J. Cell Biol.</i> , Vol. 122, pp. 497-511 (1993) | |
| | EU | Van Meir, E. et al., "Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells", <i>Nature Genetics</i> , Vol. 8, pp. 171-176 (1994) | |
| | EV | Voest, E. E. et al., "Inhibition of Angiogenesis in Vivo by Interleukin 12", <i>J. Natl. Can. Inst.</i> , Vol. 87, pp. 581-586 (1995) | |
| EXAMINER | | DATE CONSIDERED | |
| EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | 9/20/04 | |

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

| | | | |
|---|----|--|----------------|
| ATTY. DOCKET NO. | | SERIAL NO. | FILING DATE |
| 05213-0229 | | NOT YET AVAILABLE | Filed Herewith |
| APPLICANT | | GROUP | |
| O'REILLY, ET AL | | 10/042347 | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| SM | FA | Walz, D.A. et al., "Amino acid sequence of human prothrombin fragments 1 and 2", <i>Proc. Natl. Acad. Sci.</i> , Vol. 74, pp. 1969-1973 (1977) | |
| | FB | Weidner, N. et al., "Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma", <i>J. Natl. Canc. Inst.</i> , Vol. 84, pp. 1875-1887 (1992) | |
| | FC | Weidner, N. et al., "Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Carcinoma", <i>Am. J. Path.</i> , Vol. 143, No. 2, pp. 401-409 (1993) | |
| | FD | Weidner, N. et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma", <i>NE J. of Med.</i> , Vol. 324, No. 1, pp. 1-8 (1991) | |
| | FE | Wiman, B. et al., "On the Specific Interaction Between the Lysine-Binding Sites in Plasmin and Complementary Sites In α_2 -Antiplasmin and Fibrinogen", <i>Biochimica et Biophysica Acta</i> . Vol. 579, pp. 142-154 (1979) | |
| V | FF | Yoshimura, T. et al., "Cloning, Sequencing, and Expression of Human Macrophage Stimulating Protein (MSP, MST1) Confirms MSP as a Member of the Family of Kringle Proteins and Locates the MSP Gene on Chromosome 3", <i>Laboratory of Immunobiology</i> , pp. 15461-15468 (1993) | |
| | FG | | |
| | FH | | |
| | FI | | |
| | FJ | | |
| | FK | | |
| | FL | | |
| | FM | | |
| | FN | | |
| | FO | | |
| | FP | | |

EXAMINER

DATE CONSIDERED

EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

Complete if Known

| | |
|------------------------|--------------------------------|
| Application Number | 09/115,689 01042347 |
| Filing Date | May 20, 1999 |
| First Named Inventor | M. Judah Folkman |
| Group Art Unit | 1642 |
| Examiner Name | S. Huff |
| Attorney Docket Number | 05213-0229 (43170-219534) |


10/042347
01/11/02

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

| | | | |
|-----------------------|---|--------------------|---------|
| Examiner Signature |  | Date Considered | 9/20/04 |
|-----------------------|---|--------------------|---------|

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------|--------------------------|---------------------------------|
| Substitute for Form 1449/A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/315,689 10/042347 |
| | | Filing Date | May 20, 1999 |
| | | First Named Inventor | M. Judah Folkman |
| | | Group Art Unit | 1642 |
| | | Examiner Name | S. Huff |
| Sheet 2 | of 2 | Attorney Docket Number | 05213-0229 (43170-219534) |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | |
|---|-----------------------|--|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published |
| SH | 3 | Blezinger, Paul, et al. "Systemic Inhibition of tumor growth and tumor metastases by intramuscular administration of the Endostatin gene" NATURE BIOTECHNOLOGY, vol. 17, April 1999, pp 343-348. |
| | 4 | Dhanabal, Mohanraj, et al.: "Cloning, Expression, and <i>In Vitro</i> Activity of Human Endostatin" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, US ACADEMIC PRESS INC. ORLANDO, FL, vol. 258, no. 258, 1999, pp 345-352. |
| | 5 | Ding, Yuan-Hua, et al.: "Zinc-dependent dimers observed in crystals of human endostatin" PROC. NATL. ACAD. SCI USA, vol. 95, no. 18, September 1998, pp. 10443-10448. |
| | 6 | O'Reilly, Michael S., et al.: "Endostatin: and Endogenous Inhibitor of Angiogenesis and Tumor Growth" CELL, vol. 88, January 24, 1997, pp. 277-285. |
| | 7 | Sasaki, Takako, et al.: "Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin" THE EMBO JOURNAL, vol. 17, no. 15, August 1998, pp. 4249-4256. |
| | 8 | Ständker, Ludger, et al.: "Isolation and characterization of the circulating form of human endostatin" FEBS LETTERS, NL, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 420, no. 420, 1997, pp. 129-133. |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| | | | |
|--------------------|--------------|-----------------|---------|
| Examiner Signature | <i>SHuff</i> | Date Considered | 9/20/04 |
|--------------------|--------------|-----------------|---------|

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|---------------------------|
| Application No. | 10/042,347 |
| Filing Date | 01/11/2002 |
| First Named Inventor | O'Reilly et al. |
| Group Art Unit | 1642 |
| Examiner Name | Sheela Jitendra Huff |
| Attorney Docket Number | 05213-0880 (43170-249874) |

Sheet 1 of 6

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|----------------------|--------------------------|----------------------|--------------------------------------|--|--|---|
| | | Number ⁴ | Kind Code ⁵ (if known) | | | |
| | 1 | 60/80728 | | MIXSON, James A. | 06/27/2000 | |

RECEIVED

AUG 1 5 2002

TECH CENTER 1600/2900

Examiner
SignatureDate
Considered

9/20/04

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|---|----|---|------------------------|---------------------------|
| Substitution for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application No. | 10/042,347 |
| | | | | Filing Date | 01/11/2002 |
| | | | | First Named Inventor | O'Reilly et al. |
| | | | | Group Art Unit | 1642 |
| | | | | Examiner Name | Sheela Jitendra Huff |
| Sheet | 2 | of | 6 | Attorney Docket Number | 05213-0880 (43170-249874) |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published |
|-------------------|----------|--|
| SPH | 2 | Author: Title: Chapter 12: Vectors for Gene Therapy Publ: Current Protocols in Human Genetics Vol/Iss: Pages: Date: 1997 |
| | 3 | Author: BOUSSIF, O. et al. Title: A versatile vector for gene and oligonucleotide transfer into cells in culture and <i>in vivo</i> : Polyethylenimine Publ: Proc. Natl. Acad. Sci. USA Vol/Iss: 92 Pages: 7297-7301 Date: 08/1995 |
| | 4 | Author: CALOS, MICHELE P. Title: The potential of extrachromosomal replicating vectors for gene therapy Publ: TIG Vol/Iss: 12 (11) Pages: 463-466 Date: 11/1996 |
| | 5 | Author: CHEN, P. et al. Title: Genetic Mechanisms of Tumor Suppression by the Human p53 Gene Publ: Science Vol/Iss: 250 Pages: 1576-1579 Date: 12/1990 |
| | 6 | Author: CHENG, PI-WAN Title: Receptor Ligand-Facilitated Gene Transfer: Enhancement of Liposome-Mediated Gene Transfer and Expression by Transferrin Publ: Human Gene Therapy Vol/Iss: 7 Pages: 275-282 Date: 02/10/199 |
| | 7 | Author: DARDIK, R. et al. Title: The structure of endothelial cell thrombospondin - Characterization of the heparin-binding domains Publ: Eur J Biochem Vol/Iss: 168 (2) Pages: 347-355 Date: 10/15/198 |
| ✓ | 8 | Author: DEBS, R J. et al. Title: Regulation of Gene Expression <i>in Vivo</i> by Liposome-mediated Delivery of a Purified Transcription Factor Publ: The Journal of Biological Chemistry Vol/Iss: 265 (18) Pages: 10189-10192 Date: 06/25/199 |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>Sheela Huff</i> | Date Considered | 9/20/04 |
|--------------------|--------------------|-----------------|---------|

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|--------------------------|
| Application No. | 10/042,347 |
| Filing Date | 01/11/2002 |
| First Named Inventor | O'Reilly et al. |
| Group Art Unit | 1642 |
| Examiner Name | Sheela Jitendra Huff |
| Attorney Docket Number | 05213-0880 (4378-200874) |

Sheet 3 of 6

RECEIVED**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

AUG 15 2002

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number, publisher, city and/or country where published |
|-------------------|----------|---|
| 558 | 9 | <p>Author: DIXIT, V.M. et al. Title: A monoclonal antibody against human thrombospondin inhibits platelet aggregation</p> <p>Publ: Proc. Natl. Acad. Sci. USA Vol/Iss: 82 Pages: 3472-3476 Date: 05/1985</p> |
| | 10 | <p>Author: FAN et al. Title: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy</p> <p>Publ: Trends in Pharmacological Sciences Vol/Iss: 16 (2) Pages: 57-66 Date: 02/95</p> |
| | 11 | <p>Author: FIDLER et al. Title: The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis</p> <p>Publ: Cell Vol/Iss: 79(2) Pages: 185-188 Date: 10/21/94</p> |
| | 12 | <p>Author: FUJIWARA, T. et al. Title: Induction of Chemosensitivity in Human Lung Cancer Cells <i>in Vivo</i> by Adenovirus-mediated Transfer of the Wild-Type p53 Gene</p> <p>Publ: Cancer Research Vol/Iss: 54 Pages: 2287-2291 Date: 05/01/199</p> |
| | 13 | <p>Author: GOLDMAN, C.K. et al. Title: In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer</p> <p>Publ: Nature Biotechnology Vol/Iss: 15 Pages: 462-466 Date: 05/1997</p> |
| | 14 | <p>Author: HAWKINS, MICHAEL J. M.D. Title: Clinical trials of antiangiogenic agents</p> <p>Publ: Current Opinion in Oncology Vol/Iss: 7 Pages: 90-93 Date: 1995</p> |
| | 15 | <p>Author: KING, RALPH P. Jr. Title: Novel Cancer Approach From Noted Scientist Hits Stumbling Block</p> <p>Publ: Wall Street Journal Vol/Iss: Pages: A1, A8 Date: 11/12/199</p> |

Examiner
SignatureDate
Considered

9/20/04

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|--|---|----|----------------------|------------------------|--------------------------|
| Substitution for Form 1449/A/PT INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application No. | 10/042,347 | |
| | | | Filing Date | 01/11/2002 | |
| | | | First Named Inventor | O'Reilly et al. | |
| | | | Group Art Unit | 1642 | |
| | | | Examiner Name | Sheela Jitendra Huff | |
| Sheet | 4 | of | 6 | Attorney Docket Number | 05213-0880 (1170-249874) |

AUG 15 2002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published |
|-------------------|----------|--|
| SDH | 16 | Author: KOSFELD, M.D. et al. Title: Identification of a New Cell Adhesion Motif in Two Homologous Peptides from the COOH-terminal Cell Binding Domain on Human Thrombospondin Publ: The Journal of Biological Chemistry Vol/Iss: 268 (12) Pages: 8808-8814 Date: 1993 |
| | 17 | Author: LESOON-WOOD, L.A. et al. Title: Systemic Gene Therapy with p53 Reduces Growth and Metastases of a Malignant Human Breast Tumor in Nude Mice Publ: Human Gene Therapy Vol/Iss: 6 Pages: 395-405 Date: 04/1995 |
| | 18 | Author: MAIONE, T.E. et al. Title: Inhibition of Tumor Growth in Mice by an Analogue of Platelet Factor 4 That Lacks Affinity for Heparin and Retains Potent Angiostatic Activity Publ: Cancer Research Vol/Iss: 51 Pages: 2077-2083 Date: 04/15/1999 |
| | 19 | Author: MARSHALL, ELIOT Title: Gene Therapy's Growing Pains Publ: Science Vol/Iss: 269 Pages: 1050-1055 Date: 08/25/1999 |
| | 20 | Author: O'REILLY et al. Title: Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth Publ: Cell Vol/Iss: 88 Pages: 277-285 Date: 01/24/97 |
| | 21 | Author: PARK et al. Title: Development of liposome- and anti-HER2 immunoliposome/plasmid complexes for efficient and selective gene therapy Publ: Proceedings of the American Association for Cancer Research Vol/Iss: 38 Pages: 342 Date: 03/1997 |
| | 22 | Author: PASQUALINI, R. et al. Title: α_v Integrins as receptors for tumor targeting by circulating ligands Publ: Nature Biotechnology Vol/Iss: 15 Pages: 542-546 Date: 06/1997 |

| | | | |
|--------------------|--------------|-----------------|---------|
| Examiner Signature | <i>Shuff</i> | Date Considered | 9/20/04 |
|--------------------|--------------|-----------------|---------|

'Unique citation designation number. 'See attached Kinds of U.S. Patent Documents. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|---|----|---|------------------------|---------------------------|
| Substitute for Form 1449/A/P INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application No | 10/042,347 |
| | | | | Filing Date | 01/11/2002 |
| | | | | First Named Inventor | O'Reilly et al. |
| | | | | Group Art Unit | 1642 |
| | | | | Examiner Name | Sheela Jitendra Huff |
| Sheet | 5 | of | 6 | Attorney Docket Number | 05213-0880 (43170-249874) |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | |
|-------------------|----------|--|--|------------------|-----------------|
| STJ | 23 | Author: PASQUALINI, R. et al. | Title: Organ targeting <i>in vivo</i> using phage display peptide libraries | | |
| | | Publ: <u>Nature</u> | Vol/Iss: 380 | Pages: 364-166 | Date: 03/28/199 |
| | 24 | Author: SAIKI et al. | Title: Inhibition of Tumor Angiogenesis by a Synthetic Cell-adhesive Polypeptide Containing the Arg-Gly-Asp (RGD) Sequence of Fibronectin, Poly(RGD) | | |
| | | Publ: <u>Jpn. J. Cancer Research</u> | Vol/Iss: 81 | Pages: 668-675 | Date: 1990 |
| | 25 | Author: SHEIKH et al. | Title: Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines | | |
| | | Publ: <u>Oncogene</u> | Vol/Iss: 11 | Pages: 1899-1905 | Date: 1995 |
| | 26 | Author: TANAKA, T. et al. | Title: Viral vector-mediated transductions of a modified platelet factor 3 cDNA inhibits angiogenesis and tumor growth | | |
| | | Publ: <u>Nature Medicine</u> | Vol/Iss: 3 | Pages: 437-442 | Date: 04/1997 |
| | 27 | Author: WEINSTAT-SASLOW, D.L. et al. | Title: Transfection of Thrombospondin 1 Complementary DNA into a Human Breast Carcinoma Cell Line Reduces Primary Tumor Growth, Metastatic Potential, and Angiogenesis | | |
| | | Publ: <u>Cancer Research</u> | Vol/Iss: 54 | Pages: 6504-6511 | Date: 1994 |
| | 28 | Author: XU, M. et al. | Title: In Vivo Gene Therapy with a Cationic Polymer Markedly Enhances the Antitumor Activity of Antiangiogenic Genes | | |
| | | Publ: <u>Molecular Genetics and Metabolism</u> | Vol/Iss: 64 | Pages: 001-005 | Date: 1998 |
| | 29 | Author: XU, M. et al. | Title: Gene Therapy with P53 and a Fragment of Thrombospondin 1 Inhibits Human Breast Cancer <i>in Vivo</i> | | |
| | | Publ: <u>Molecular Genetics and Metabolism</u> | Vol/Iss: 63 | Pages: 103-109 | Date: 1998 |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>Sheela Huff</i> | Date Considered | 9/20/04 |
|--------------------|--------------------|-----------------|---------|

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|-----------------------|--|---------------------------|
| Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application No. | 10/042,347 |
| | | Filing Date | 01/11/2002 |
| | | First Named Inventor | O'Reilly et al. |
| | | Group Art. Unit | 1642 |
| Examiner Name | Sheela Jitendra Huff | Attorney Docket Number | 05213-0880 (43170-249874) |
| Sheet | 6 | of | 6 |
| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T |
| SH | 30 | Author: XU, M. et al. Title: Parenteral Gene Therapy with p53 Inhibits Human Breast Tumors <i>In Vivo</i> Through a Bystander Mechanism Without Evidence of Toxicity Publ: Human Gene Therapy Vol/Iss: 8 Pages: 177-185 Date: 01/20/199 | |
| | 31 | Author: ZABRENETZKY, V. et al. Title: EXPRESSION OF THE EXTRACELLULAR MATRIX MOLECULE THROMBOSPONDIN INVERSELY CORRELATES WITH MALIGNANT PROGRESSION IN MELANOMA, LUNG AND BREAST CARCINOMA CELL Publ: Int. J. Cancer Vol/Iss: 59 Pages: 191-195 Date: 1994 | |
| V | 32 | Author: ZHU, N. et al. Title: Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice Publ: Science Vol/Iss: 261 Pages: 209-211 Date: 07/09/199 | |

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

| | | | |
|--------------------|--------------|-----------------|---------|
| Examiner Signature | <i>SHuff</i> | Date Considered | 9/20/04 |
|--------------------|--------------|-----------------|---------|

¹Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.